Viola Weich
Overview
Explore the profile of Viola Weich including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiegand J, Neumann K, Bohm S, Weich V, Teuber G, Klinker H, et al.
Clin Infect Dis
. 2011 Oct;
53(11):1111-4.
PMID: 22021919
This study demonstrates that a more precise prediction of the individual relapse risk in chronic hepatitis C virus genotype 1 infection can be obtained by kinetics of minimal residual viremia...
2.
Weich V, Herrmann E, Chung T, Sarrazin C, Hinrichsen H, Buggisch P, et al.
J Gastroenterol
. 2011 Sep;
46(12):1427-36.
PMID: 21912897
Background: The critical analysis of baseline factors has been found to be useful to predict virologic nonresponse (NR), relapse, or sustained virologic response (SVR) in patients infected with hepatitis C...
3.
Lange C, Roomp K, Dragan A, Nattermann J, Michalk M, Spengler U, et al.
J Hepatol
. 2010 Aug;
53(6):1022-8.
PMID: 20800922
Background & Aims: The adaptive immune response against hepatitis C virus (HCV) is significantly shaped by the host's composition of HLA-alleles with the consequence that the HLA phenotype is a...
4.
Berg T, Weich V, Teuber G, Klinker H, Moller B, Rasenack J, et al.
Hepatology
. 2009 Jul;
50(2):369-77.
PMID: 19575366
Unlabelled: Individualized treatment on the basis of early viral kinetics has been discussed to optimize antiviral therapy in chronic hepatitis C virus (HCV) infection. Individually tailored reduction in treatment duration...
5.
Mas Marques A, Mueller T, Welke J, Taube S, Sarrazin C, Wiese M, et al.
Infect Genet Evol
. 2009 May;
9(5):847-52.
PMID: 19446659
Low-density lipoprotein receptor (LDLR) is involved in the entry of hepatitis C virus (HCV) in host cells. We investigated whether three single-nucleotide alterations within LDLR might be associated with the...
6.
Halangk J, Sarrazin C, Neumann K, Puhl G, Mueller T, Teuber G, et al.
J Hepatol
. 2008 Jul;
49(3):339-45.
PMID: 18644651
Background/aims: Intercross studies in inbred mice susceptible or resistant to liver fibrosis revealed complement factor 5 as a quantitative trait gene associated with the development of fibrosis. In 277 patients...
7.
Schott E, Witt H, Pascu M, Boemmel F, Weich V, Bergk A, et al.
Eur J Gastroenterol Hepatol
. 2007 Dec;
19(11):947-51.
PMID: 18049163
Background: CTLA4 is an inhibitory receptor expressed on a subset of T lymphocytes. Single nucleotide polymorphisms of the CTLA4 gene have been implicated in autoimmune diseases, including autoimmune hepatitis and...
8.
Schaefer M, Hinzpeter A, Mohmand A, Janssen G, Pich M, Schwaiger M, et al.
Hepatology
. 2007 Aug;
46(4):991-8.
PMID: 17668880
Unlabelled: We investigated and compared the results of treating the chronic hepatitis C (HCV) infection of different groups of psychiatric-risk patients and controls with pegylated interferon alpha (pegIFN-alpha) plus ribavirin....
9.
Plockinger U, Kruger D, Bergk A, Weich V, Wiedenmann B, Berg T
Am J Gastroenterol
. 2007 Jul;
102(12):2724-31.
PMID: 17662104
Objectives: In vitro and in vivo data indicate multiple, but contradictory effects of interferon on pituitary hormone secretion. We therefore investigated prospectively basal and stimulated pituitary hormone secretion in 21...
10.
Schott E, Witt H, Neumann K, Taube S, Oh D, Schreier E, et al.
J Hepatol
. 2007 May;
47(2):203-11.
PMID: 17512627
Background/aims: HCV-infection leads to development of liver fibrosis, causing morbidity and mortality. Multiple factors influence the progression of fibrosis, including genetic factors. Since HCV is an RNA virus, a role...